Spotlight on Lanreotide Autogel® in Acromegaly

被引：0
|
作者：
Jamie D. Croxtall
Lesley J. Scott
机构：
[1] Wolters Kluwer Health ¦ Adis,
[2] Wolters Kluwer Health,undefined
来源：
BioDrugs | 2008年 / 22卷
关键词：
Growth Hormone; Acromegaly; Growth Hormone Level; Lanreotide; Somatuline;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Lanreotide Autogel® (ATG) [Somatuline® Depot]1 is a novel, long-acting preparation of the somatostatin analog lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most other licensed agents, it has a favorable pharmacokinetic profile that permits administration once every 28–42 days.
引用
收藏
页码：275 / 277
页数：2
相关论文
共 50 条
  • [1] Lanreotide autogel in acromegaly - a decade on
    Kyriakakis, Nikolaos
    Chau, Vincent
    Lynch, Julie
    Orme, Steve M.
    Murray, Robert D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (18) : 2681 - 2692
  • [2] Lanreotide Autogel (R) in the Treatment of Acromegaly
    Roelfsema, Ferdinand
    Biermasz, Nienke R.
    Pereira, Alberto M.
    Romijn, Johannes A.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 343 - 357
  • [3] Lanreotide Autogel® in acromegaly: a guide to its use in the EU
    Scott L.J.
    Burnesss C.B.
    Dhillon S.
    Keam S.J.
    Drugs & Therapy Perspectives, 2015, 31 (12) : 409 - 416
  • [4] Lanreotide Autogel®A Review of its Use in the Management of Acromegaly
    Jamie D. Croxtall
    Lesley J. Scott
    Drugs, 2008, 68 : 711 - 723
  • [5] Lanreotide Autogel®: A Review of its Use in the Treatment of Patients with Acromegaly
    Celeste B. Burness
    Sohita Dhillon
    Susan J. Keam
    Drugs, 2014, 74 : 1673 - 1691
  • [6] Therapeutic options in the management of acromegaly: focus on lanreotide Autogel (R)
    Roelfsema, Ferdinand
    Biermasz, Nienke R.
    Pereira, Alberto M.
    Romijn, Johannes A.
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (03) : 463 - 479
  • [7] Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly
    Witek, Przemyslaw
    Mucha, Slawomir
    Ruchala, Marek
    ENDOKRYNOLOGIA POLSKA, 2016, 67 (06) : 572 - 579
  • [8] Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
    Bernabeu, Ignacio
    Fajardo, Carmen
    Marazuela, Monica
    Cordido, Fernando
    Maria Venegas, Eva
    de Pablos-Velasco, Pedro
    Piedrola Maroto, Gonzalo
    Pilar Olvera, Maria
    Pavon de Paz, Isabel
    Carvalho, Davide
    Romero, Carme
    De la Cruz, Guillermo
    Alvarez Escola, Cristina
    ENDOCRINE, 2020, 70 (03) : 575 - 583
  • [9] Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
    Ignacio Bernabéu
    Carmen Fajardo
    Mónica Marazuela
    Fernando Cordido
    Eva María Venegas
    Pedro de Pablos-Velasco
    Gonzalo Piedrola Maroto
    María Pilar Olvera
    Isabel Pavón de Paz
    Davide Carvalho
    Carme Romero
    Guillermo De la Cruz
    Cristina Álvarez Escolá
    Endocrine, 2020, 70 : 575 - 583
  • [10] Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review
    Mazziotti, Gherardo
    Giustina, Andrea
    PITUITARY, 2010, 13 (01) : 60 - 67
12345